Top section
Top section
Former investment banker has been CFO of Verbund
Investment banking is a competitive business, especially when it’s your bosses that are vying for your attention
More articles
More articles
More articles
-
Glenmark Life Sciences, a pharmaceutical ingredients manufacturer, wrapped up a three-day bookbuild for its India IPO on Thursday. The deal, worth up to Rp15.5bn ($208.6m), was covered 15.5 times. -
Chinese stocks were in freefall this week after Beijing tightened rules for the for-profit education sector, sparking a fresh — and severe — bout of volatility in the equities market. While the timing for new IPOs is far from ideal, there is hope yet for companies, say ECM bankers. Jonathan Breen reports.
-
HK Inno.N Corp, a South Korean pharmaceuticals company known for its popular hangover tonics, has priced its IPO at the top of the marketed range, netting W596.9bn ($520.9m).
-
After several quarters of strong performance among European investment banking businesses, there are signs that firms are satisfied with cost cutting measures and are prepared to resume investment instead.
-
Convertible bonds are expected to remain a popular financing tool for European companies once the market reopens in September, as long as the bull run in stocks continues.
-
Aligning with a global commercial bank has been on Jefferies’ agenda for several years, but its alliance with SMBC signals an intent to join the investment banking big league. By David Rothnie.
Sub-sections
shared comment list
